U.S. markets open in 8 hours 42 minutes

Neovasc Inc. (NVCN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.0100-0.0300 (-2.88%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Flag (Bearish)

Flag (Bearish)

Previous Close1.0400
Bid0.0000 x 900
Ask0.0000 x 1300
Day's Range1.0100 - 1.0350
52 Week Range0.6800 - 3.8800
Avg. Volume5,983,531
Market Cap69.306M
Beta (5Y Monthly)2.85
PE Ratio (TTM)N/A
EPS (TTM)-1.7220
Earnings DateMar 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.88
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Neovasc (NVCN) Reports Q4 Loss, Misses Revenue Estimates

    Neovasc (NVCN) Reports Q4 Loss, Misses Revenue Estimates

    Neovasc (NVCN) delivered earnings and revenue surprises of 66.67% and -6.55%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Neovasc Announces Fourth Quarter and Fiscal Year 2020 Financial Results

    Neovasc Announces Fourth Quarter and Fiscal Year 2020 Financial Results

    VANCOUVER and MINNEAPOLIS, March 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), today reported financial results for the fourth quarter and fiscal year ended December 31, 2020. Fourth Quarter Highlights Generated revenue of $514,000 in the quarter and $1.96 million for the full year as Reducer implants rebounded after declining due to the COVID-19 pandemic.In December, announced the completion of the first Neovasc Reducer™ (“Reducer”) implants in France.Completed a registered direct share offering in December, which raised $6.1 million gross proceeds.Announced the publication of a peer-reviewed article in EuroIntervention, which presented data from the ongoing Reducer-I trial that supported the safety and efficacy of Reducer. Subsequent to the Fourth quarter Regained compliance with the minimum bid price requirement and the minimum market value requirement under Nasdaq Listing Rules Completed a registered direct offering in February 2021 which raised approximately $72 million gross proceeds. “Neovasc continued to advance its efforts to commercialize the Reducer and further develop the Tiara devices in the fourth quarter,” said Fred Colen, President and Chief Executive Officer of Neovasc. “We are encouraged by the results of the quarter despite the impact from COVID-19. We believe there is clearly strong underlying demand for Reducer.” Colen continued, “We continue to advance the CE mark submission for Tiara TA in Europe, with the goal of securing a regulatory decision in the first half of the year. We also continue to make meaningful progress on our Tiara TF development program and we are targeting a first-in-human implant in the second half of 2021. Finally, subsequent to the quarter, in February 2021, we took an important step, raising $72 million gross proceeds to secure Neovasc’s ability to execute on our strategies for the medium term. We look forward to continuing our progress in 2021.” Financial results for the fourth quarter ended December 31, 2020Revenues decreased by 6% to $1,957,362 for the year ended December 31, 2020, compared to revenues of $2,092,032 for the same period in 2019 as elective procedures, including the implantation of Reducer, were temporarily suspended at many hospitals due to the impact of COVID-19. The gross margin for the year ended December 31, 2020 was 77%, compared to 78% gross margin for the same period in 2019 as we continue to focus on the development of territories where we sell the Reducer with a direct sales force. Total expenses for the year ended December 31, 2020 were $36,679,551 compared to $31,680,676 for the same period in 2019, representing an increase of $4,998,875 or 16%, principally because of a $2,528,240 increase in legal costs related to financings, as we completed five financings during 2020, a $1,716,004 increase in share-based payments and a $1,130,794 increase in cash-based employee expenses as we hired a new COO and other higher paid staff, while still reducing head count overall. Operating losses and comprehensive losses for the year ended December 31, 2020 were $35,168,428 and $30,170,251, respectively, or $1.72 basic and diluted loss per share, as compared with $30,047,080 operating losses and $33,618,494 comprehensive losses, or $5.40 basic and diluted loss per share, for the same period in 2019. Conference Call and Webcast informationNeovasc will be hosting a conference call and audio webcast today at 4:30 pm ET to discuss these results. Domestic: 1-877-407-9208International: 1-201-493-6784 Parties wishing to access the call via webcast should use the link in the Investors section of the Neovasc website at https://www.neovasc.com/investors/. A replay of the webcast will be available approximately 30 minutes after the conclusion of the call. About Neovasc Inc.Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. The Company is a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina. Its products include the Neovasc Reducer™, for the treatment of refractory angina, which is not currently commercially available in the United States (2 U.S. patients have been treated under Compassionate Use) and has been commercially available in Europe since 2015, and Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit: www.neovasc.com. NEOVASC INC. Consolidated Statements of Financial Position As at December 31,(Expressed in U.S. dollars) 202020192018 ASSETS Current assets Cash and cash equivalents $ 12,935,860$ 5,292,833$ 9,242,809 Accounts receivable 987,057715,696 647,143 Finance lease receivable 95,84986,764- Inventory 839,472618,650318,135 Research and development supplies 167,378671,8451,274,653 Prepaid expenses and other assets 705,471630,042 591,236 Total current assets 15,731,0878,015,830 12,073,976 Non-current assets Restricted cash 470,460 462,874439,736 Right-of-use asset 830,551 720,473 - Finance lease receivable 42,841 138,690- Property and equipment 803,280 767,973813,628 Total non-current assets 2,147,1322,090,010 1,253,364 Total assets $ 17,878,219$ 10,105,840$ 13,327,340 LIABILITIES AND EQUITY Liabilities Current liabilities Accounts payable and accrued liabilities $ 7,243,500$ 7,794,456$ 4,610,560 Lease liabilities 342,910436,352- 2017 Convertible notes -5,400,1891,423,224 2019 Convertible notes 38,6331,090,561- 2020 Convertible notes 37,525-- Total current liabilities 7,662,56814,721,5586,033,784 Non-Current Liabilities Accounts payable and accrued liabilities -1,186,6012,241,979 Lease liabilities 596,881468,527- 2017 Convertible notes --13,194,112 2017 Derivative warrant liability --190,303 2019 Convertible notes 6,156,7248,174,919- 2020 Convertible notes and warrants and derivative warrant liabilities 1,484,529--Total non-current liabilities 8,238,1349,830,04715,626,394 Total liabilities $ 15,900,702$ 24,551,605$ 21,660,178 Equity Share capital $ 369,775,383$ 328,460,681$ 304,460,533 Contributed surplus 35,045,05629,766,22526,260,806 Accumulated other comprehensive loss (7,615,717)(6,140,507) (7,653,028) Deficit (395,227,205)(366,532,164) (331,401,149) Total equity 1,977,517(14,445,765) (8,332,838) Total liabilities and equity $ 17,878,219$ 10,105,840$ 13,327,340 NEOVASC INC. Consolidated Statements of Loss and Comprehensive Loss For the years ended December 31, (Expressed in U.S. dollars) 202020192018 REVENUE $ 1,957,362$ 2,092,032 $ 1,749,133COST OF GOODS SOLD 446,239458,436366,258GROSS PROFIT 1,511,1231,633,5961,382,875 EXPENSES Selling expenses 2,196,8031,645,9851,353,165General and administrative expenses 14,081,15310,013,73216,438,936Product development and clinical trials expenses 20,401,59520,020,95916,001,464TOTAL EXPENSES 36,679,55131,680,67633,793,565 OPERATING LOSS (35,168,428)(30,047,080)(32,410,690) OTHER (EXPENSE)/ INCOME Interest and other income 1,394,035184,912183,065Interest and prepayment penalty expense (1,035,957)(133,082)-Impairment on right-of-use asset -(104,544)-Gain on sale of asset --238,907Loss on foreign exchange (256,585)(74,209)(175,054)Unrealized gain/(loss) on warrants, derivative liability warrants and convertible notes 8,528,255(3,235,591)(814,827)Realized gain/(loss) on exercise or conversion of warrants, derivative liability warrants and convertible notes 814,083(1,692,628)(28,003,594)Amortization of deferred loss (3,494,501)-(46,894,189)TOTAL OTHER (EXPENSE)/ INCOME 5,949,330(5,055,142)(75,465,692)LOSS BEFORE TAX (29,219,098)(35,102,222)(107,876,382) Tax recovery/(expense) 524,057(28,793)(107,093)LOSS FOR THE YEAR $ (28,695,041)$ (35,131,015)$ (107,983,475) OTHER COMPREHENSIVE (LOSS)/INCOME FOR THE YEAR Fair market value changes in convertible notes due to changes in own credit risk (1,475,210)1,512,521(1,009,592) (1,475,210)1,512,521(1,009,592)LOSS AND OTHER COMPREHENSIVE LOSS FOR THE YEAR $ (30,170,251)$ (33,618,494)$ (108,993,067) LOSS PER SHARE Basic and diluted loss per share $ (1.72)$ (5.40)$ (76.26) InvestorsMike CavanaughWestwicke/ICR Phone: +1.646.877.9641Mike.Cavanaugh@westwicke.com MediaSean LeousWestwicke/ICR Phone: +1.646.677.1839Sean.Leous@icrinc.com Forward-Looking Statement DisclaimerCertain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact. When used herein, the words "expect", "anticipate", "estimate", "may", "will", "should", "intend," "believe", and similar expressions, are intended to identify forward-looking statements. Forward-looking statements may involve, but are not limited to, expectations as to the future growth of the Company, the expansion of its product range and the growing cardiovascular marketplace. Forward-looking statements are based on estimates and assumptions made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company believes are appropriate in the circumstances. Many factors could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including those described in the "Risk Factors" section of the Company's Annual Report on Form 20-F and in the Management's Discussion and Analysis for the three and six months ended June 30, 2019 (copies of which may be obtained at www.sedar.com or www.sec.gov). These factors should be considered carefully, and readers should not place undue reliance on the Company's forward-looking statements. The Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


    Neovasc, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 11, 2021 / Neovasc, Inc. (NASDAQ:NVCN) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 11, 2021 at 4:30 PM Eastern Time.